Hemolytic uremic syndrome due to gemcitabine in a young woman with cholangiocarcinoma [documento electrónico] / John Fredy Nieto Ríos, ; Catalina Ocampo Kohn, ; Cristian Iván García Rincón, ; Kenny Mauricio Gálvez Cárdenas, ; Arbey Aristizabal Álzate, ; Gustavo Adolfo Zuluaga Valencia,  . - 2016.
Obra : Brazilian Journal of Nephrology

Idioma : Inglés (eng)

Palabras clave :	Acute kidney injury  cholangiocarcinoma  hemolyticuremic syndrome  thrombotic microangiopathies
Resumen :	Gemcitabine is a medication used to treat various types of malignant neoplasms. Its association with hemolytic uremic syndrome (HUS) has been described in few cases, although these cases have resulted in mortality rates of at least 50%. We report on the case of a 25-year-old patient with cholangiocarcinoma in remission who developed microangiopathic hemolytic anemia with acute anuric renal failure after receiving 5 cycles of gemcitabine chemotherapy; this condition was consistent with HUS caused by the side effects of this drug. The administration of gemcitabine was stopped, and hemodialysis, blood transfusions, plasma exchanges, steroids, doxycycline, and rituximab were used to treat the patient. A favorable outcome was achieved; in particular, hemolysis was controlled, and renal function was completely recovered.
Mención de responsabilidad :	John Fredy Nieto-Ríos, Mónica Zuluaga-Quintero, Lina Maria Serna Higuita, Cristian Ivan García Rincón, Kenny Mauricio Galvez-Cárdenas, Catalina Ocampo-Kohn, Arbey Aristizabal-Alzate, Adriana Alejandra Florez-Vargas, Gustavo Adolfo Zuluaga-Valencia
Referencia :	J Bras Nefrol. 2016 Jun;38(2):255-9.
DOI (Digital Object Identifier) :	10.5935/0101-2800.20160035
PMID :	27438981
Derechos de uso :	CC BY
En línea :	http://bjn.org.br/details/1860/en-US/hemolytic-uremic-syndrome-due-to-gemcitabin [...]
Enlace permanente :	https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3965